台湾神经退行性疾病的疾病负担
Sung-Pin Fan1, Po-Chen Liu2, Jing-Zhong Wang2
1Department of Neurology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 10025, Taiwan; Institute of Clinical Medicine, College of Medicine, National Taiwan University, No.1, Chang-Te Street, Taipei, 10048, Taiwan; Graduate School of Advanced Technology, National Taiwan University, No.1, Sec. 4, Roosevelt Rd., Taipei City, 106319, Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi
|January 17, 2026
概括
2000年至2021年,阿尔茨海默病与其他痴呆症 (ADOD) 和帕金森病 (PD) 的患病率在台湾显著增加. 神经退行性疾病负担的增加对台湾老龄化人口构成了挑战.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 全球人口老龄化导致神经退行性疾病的患病率增加,如阿尔茨海默病 (AD) 和帕金森病 (PD).
- 台湾缺乏对AD和PD负担趋势的全面评估.
- 本研究调查了台湾其他痴呆症 (ADODs) 和PD负担的AD的时间和地理趋势.
研究的目的:
- 评估2000年至2021年台湾ADOD和PD负担的时间和地理趋势.
- 根据年龄,性别和地区对疾病负担进行分层.
- 为管理老龄人口中神经退行性疾病的公共卫生策略提供信息.
主要方法:
- 分析台湾国家健康保险 (NHI) 和国家死亡登记数据 (2000-2021年).
- 对ADOD和PD的病例定义遵循了使用ICD代码的2021年全球疾病负担标准.
- 疾病负担量化为YLLs,YLDs和DALYs,并对区域变异进行地理映射.
主要成果:
- 根据年龄标准化,ADOD和PD的患病率分别上升了885%和394%;死亡率上升了116%和31%.
- 对于ADODs (258%) 和PD (86%),DALY率显著上升,主要是由于YLDs的增加.
- 在80岁以上的个体中观察到的负担最高,台湾南部在两种条件下表现出最高的年龄标准化DALY.
结论:
- 台湾面临着ADOD和PD的患病率和健康负担大幅增加.
- 疾病负担的增加,特别是在老年人中,带来了重大挑战.
- 尽管发病率下降,但有效的公共卫生干预措施对老龄化人口至关重要.
相关概念视频
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:28Disorders of the Nervous Tissue
2.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.5K
01:37Neural Regulation
43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827